Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model
暂无分享,去创建一个
R. Gieschke | R. Gieschke | J. Steimer | P. Jacqmin | E. Snoeck | J. Steimer | P. Girard | P. Jacqmin | E. Snoeck | E. A. van Schaick | P. Pillai | J.-L. Steimer | P. Girard | P. Pillai | E. Schaick
[1] M. Danhof,et al. Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic effects of the adenosine A1-receptor agonist N6-(P-sulfophenyl)adenosine (SPA) in rats , 1995 .
[2] C. Meistelman,et al. Comparison of Twitch Depression of the Adductor Pollicis and the Respiratory Muscles Pharmacodynamic Modeling without Plasma Concentrations , 1994, Anesthesiology.
[3] M. Gibaldi,et al. Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. , 1972, Journal of pharmaceutical sciences.
[4] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[5] Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A1‐receptor agonist N6‐(p‐sulphophenyl)adenosine in rats , 1997, British journal of pharmacology.
[6] Lewis B. Sheiner,et al. Semiparametric analysis of non-steady-state pharmacodynamic data , 2005, Journal of Pharmacokinetics and Biopharmaceutics.
[7] Sylvie Chabaud,et al. Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[8] Johan Gabrielsson,et al. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .
[9] D. Fisher,et al. Are Plasma Concentration Values Necessary for Pharmacodynamic Modeling of Muscle Relaxants? , 1997, Anesthesiology.
[10] Michael G. M. Derks,et al. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions. , 1997, The Journal of pharmacology and experimental therapeutics.
[11] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.
[12] Timothy Goggin,et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.
[13] G. Tucker,et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. , 2002, British journal of anaesthesia.
[14] R. Lalonde,et al. Mixed‐effects modeling of the pharmacodynamic response to the calcimimetic agent R–568 , 1999, Clinical pharmacology and therapeutics.
[15] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[16] A. Dahan,et al. Pharmacodynamic Effect of Morphine-6-glucuronide versus Morphine on Hypoxic and Hypercapnic Breathing in Healthy Volunteers , 2003, Anesthesiology.
[17] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[18] Lewis B. Sheiner,et al. A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.
[19] W. Jusko,et al. Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles , 2000, Biopharmaceutics & drug disposition.
[20] Stuart L. Beal,et al. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[21] J. Blanck,et al. Kinetics of Drug Action , 1977, Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology.
[22] P. Jordan,et al. Explicit solutions for a class of indirect pharmacodynamic response models , 2005, Comput. Methods Programs Biomed..
[23] L Aarons,et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[24] G. Levy. RELATIONSHIP BETWEEN RATE OF ELIMINATION OF TUBOCURARINE AND RATE OF DECLINE OF ITS PHARMACOLOGICAL ACTIVITY. , 1964, British journal of anaesthesia.
[25] M. Danhof,et al. A Combined Specific Target Site Binding and Pharmacokinetic Model to Explore the Non-linear Disposition of Draflazine , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[26] J. Wade,et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[27] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[28] Johan Gabrielsson,et al. Comprar Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Fourth Edition | Johan Gabrielsson | 9789197651004 | Informa Healthcare , 2007 .
[29] G. Levy. Kinetics of pharmacologic activity of succinylcholine in man. , 1967, Journal of pharmaceutical sciences.